99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Trial Parameters
Brief Summary
At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.
Eligibility Criteria
Inclusion Criteria: * Voluntary subjects, patients or their legal representatives sign informed consent; * Volunteers are of any gender and aged between 18 and 75 years old, including the cut-off value; * Other imaging methods found tumor occupying; * Patients with pre-treatment tumors for whom surgery or biopsy may be performed to obtain final pathological results. * Kidney glomerular filtration rate(GFR)\>50 ml/min, effective renal plasma flow(ERPF)\>280 ml/min, platelet count (PLT) \>75 000/μL, white blood cell (WBC) \>3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3 times the normal value. Exclusion Criteria: * People who have a history of allergy to similar drugs , allergic constitution or are currently suffering from allergic diseases; * Is conducting clinical research on other drugs, or has participated in clinical research on any drugs (excluding vitamins and minerals); * Have other clinical problems that are difficult to control (such as hepati